Novozymes A/S
XMUN:NZM2
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Novozymes A/S
XMUN:NZM2
|
DK |
|
R
|
Royal Bank of Canada
SWB:RYC
|
CA |
|
Siloam International Hospitals Tbk PT
F:2LS
|
ID |
|
Novozymes A/S
F:NZM
|
DK |
|
Q
|
Qingdao Port International Co Ltd
F:0QP
|
CN |
|
Cintas Corp
NASDAQ:CTAS
|
US |
|
Panthera Resources PLC
OTC:PATRF
|
UK |
|
K
|
Kaspi.kz AO
F:KKS
|
KZ |
|
R
|
Rollins Inc
F:RLS
|
US |
|
D
|
Danaher Corp
XETRA:DAP
|
US |
|
C
|
Chilwa Minerals Ltd
ASX:CHW
|
AU |
|
P
|
Pfizer Inc
XMUN:PFE
|
US |
|
E
|
Exor NV
DUS:EYX
|
NL |
|
M
|
Moody's Corp
XMUN:DUT
|
US |
|
TTM Technologies Inc
F:TT1
|
US |
|
M
|
Mercedes-Benz Group AG
DUS:MBG
|
DE |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is NZM2's stock price target?
Price Target
68.44
EUR
According to Wall Street analysts, the average 1-year price target for
NZM2 is 68.44 EUR with a low forecast of 56.11 EUR and a high forecast of 76.09 EUR.
What is the Revenue forecast for Novozymes A/S?
Projected CAGR
-55%
Over the last 7 years, the compound annual growth rate for Revenue has been 3%. The projected CAGR for the next 2 years is -55%.
What is the Net Income forecast for Novozymes A/S?
Projected CAGR
-56%
Over the last 7 years, the compound annual growth rate for Net Income has been 0%. The projected CAGR for the next 2 years is -56%.